IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER

虽然有可能分离出对自体肿瘤细胞具有特异性细胞毒性的t淋巴细胞克隆，但所涉及的技术是费力的。更方便的特异性细胞毒性t细胞（ctl）测定方法将简化对肿瘤免疫反应的研究，并将有助于研究正在接受免疫治疗（如肿瘤疫苗治疗）的癌症患者的全身免疫反应。新的ELISPOT检测使用患者的外周血t细胞，这些t细胞通过体外暴露于来自同一患者癌症手术获得的样本的膜而受到刺激。在之前的研究中，我们已经证明了用细胞膜刺激小鼠和男性的t细胞是有效的和特异性的。我们还观察到，接受一系列癌症疫苗接种方案的患者的t细胞可以被来自这些患者癌症的膜特异性地刺激。在目前的研究中，我们将把这一分析扩展到更多种类的癌症患者，在不同的阶段，建立一个基线来评估对肿瘤的免疫反应。

Although it is possible to isolate clones of T-lymphocytes which have specific cytotoxicity directed against autologous tumor cells, the techniques involved are laborious. More convenient assays for specific cytotoxic T-cells (CTLs) would simplify the study of immune response to tumors and would facilitate the investigation of systemic immune responses in cancer patients who are undergoing immunotherapy such as tumor vaccine therapy. The novel ELISPOT assay uses peripheral blood T-cells from patients which are stimulated by exposure in vitro to membranes derived from a surgically obtained sample of the same patient's cancer. In a previous we have shown that stimulation of T-cells of mice and men with cellular membranes is effective and specific. We have also observed that T-cells of patients undergoing a vaccination protocol with an array of cancers could be stimulated specifically by the membranes derived from those patients' cancers. In the present study we will expand this analysis to a larger number of cancer patients with a broader variety of cancers, and at different stages, to establish a baseline for evaluating immune response to tumors.